144 related articles for article (PubMed ID: 33353858)
1. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.
Marasco G; Colecchia A; Bacchi Reggiani ML; Celsa C; Farinati F; Giannini EG; Benevento F; Rapaccini GL; Caturelli E; Di Marco M; Biasini E; Marra F; Morisco F; Foschi FG; Zoli M; Gasbarrini A; Baroni GS; Masotto A; Sacco R; Raimondo G; Azzaroli F; Mega A; Vidili G; Brunetto MR; Nardone G; Dajti E; Ravaioli F; Avanzato F; Festi D; Trevisani F;
Dig Liver Dis; 2021 Aug; 53(8):1011-1019. PubMed ID: 33353858
[TBL] [Abstract][Full Text] [Related]
2. External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study.
Borzio M; Dionigi E; Rossini A; Marignani M; Sacco R; De Sio I; Bertolini E; Francica G; Giacomin A; Parisi G; Vicari S; Toldi A; Salmi A; Boccia S; Mitra M; Fornari F
Hepatology; 2018 Jun; 67(6):2215-2225. PubMed ID: 29165831
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib.
Sansone V; Tovoli F; Casadei-Gardini A; Di Costanzo GG; Magini G; Sacco R; Pressiani T; Trevisani F; Rimini M; Tortora R; Nardi E; Ielasi L; Piscaglia F; Granito A
Clin Transl Gastroenterol; 2021 Jan; 12(1):e00286. PubMed ID: 33443944
[TBL] [Abstract][Full Text] [Related]
4. Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.
Howell J; Pinato DJ; Ramaswami R; Arizumi T; Ferrari C; Gibbin A; Burlone ME; Guaschino G; Toniutto P; Black J; Sellers L; Kudo M; Pirisi M; Sharma R
Oncotarget; 2017 May; 8(22):36161-36170. PubMed ID: 28212535
[TBL] [Abstract][Full Text] [Related]
5. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma.
Farinati F; Vitale A; Spolverato G; Pawlik TM; Huo TL; Lee YH; Frigo AC; Giacomin A; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Biasini E; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Masotto A; Trevisani F; Cillo U;
PLoS Med; 2016 Apr; 13(4):e1002006. PubMed ID: 27116206
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
Baek KK; Kim JH; Uhm JE; Park SH; Lee J; Park JO; Park YS; Kang WK; Lim HY
Oncology; 2011; 80(3-4):167-74. PubMed ID: 21701230
[TBL] [Abstract][Full Text] [Related]
8. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib.
Caputo F; Dadduzio V; Tovoli F; Bertolini G; Cabibbo G; Cerma K; Vivaldi C; Faloppi L; Rizzato MD; Piscaglia F; Celsa C; Fornaro L; Marisi G; Conti F; Silvestris N; Silletta M; Lonardi S; Granito A; Stornello C; Massa V; Astara G; Delcuratolo S; Cascinu S; Scartozzi M; Casadei-Gardini A
PLoS One; 2020; 15(5):e0232449. PubMed ID: 32379785
[TBL] [Abstract][Full Text] [Related]
9. Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study.
Vitale A; Farinati F; Noaro G; Burra P; Pawlik TM; Bucci L; Giannini EG; Faggiano C; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Cabibbo G; Virdone R; Marra F; Felder M; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Fornari F; Marignani M; Vicari S; Bortolini E; Cozzolongo R; Grasso A; Aliberti C; Bernardi M; Frigo AC; Borzio M; Trevisani F; Cillo U;
Hepatology; 2018 Oct; 68(4):1232-1244. PubMed ID: 30048016
[TBL] [Abstract][Full Text] [Related]
10. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.
Labeur TA; Berhane S; Edeline J; Blanc JF; Bettinger D; Meyer T; Van Vugt JLA; Ten Cate DWG; De Man RA; Eskens FALM; Cucchetti A; Bonnett LJ; Van Delden OM; Klümpen HJ; Takkenberg RB; Johnson PJ
Liver Int; 2020 Jan; 40(1):215-228. PubMed ID: 31579990
[TBL] [Abstract][Full Text] [Related]
11. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.
Diaz-Beveridge R; Bruixola G; Lorente D; Caballero J; Rodrigo E; Segura Á; Akhoundova D; Giménez A; Aparicio J
Clin Transl Oncol; 2018 Mar; 20(3):322-329. PubMed ID: 28801777
[TBL] [Abstract][Full Text] [Related]
12. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
13. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models.
Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee PC; Loong CC; Chiang JH; Huo TI; Lee SD
Cancer; 2010 Jun; 116(12):3006-14. PubMed ID: 20564406
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M
J Hepatol; 2022 Feb; 76(2):353-363. PubMed ID: 34648895
[TBL] [Abstract][Full Text] [Related]
15. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
[TBL] [Abstract][Full Text] [Related]
17. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
Pinter M; Sieghart W; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Matejka J; Stauber R; Buder R; Grünberger B; Schöniger-Hekele M; Müller C; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2011 Oct; 34(8):949-59. PubMed ID: 21883324
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
20. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
